Clinical Trial Update: Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 multi-center trial evaluating an anti-PD-1 therapy given during lymphopenia after high-dose therapy with autologous stem cell transplant in multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• PD-1 inhibitor (anti-PD-1 therapy)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-27